MoneyWorks4Me

Guj. Themis Biosyn - Quaterly Results

13 May 2023 Evaluate
Revenue showed a marginal decline at Rs. 281.73 millions. For the quarter ended March 2023, as compared to corresponding quarter of last year.A slim rise of 19.46% was recorded in the Net profit for the quarter ended March 2023 to Rs. 116.92  millions  From Rs. 97.87 millions.Operating Profit saw a handsome growth to 163.25 millions from 145.88 millions in the quarter ended March 2023.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 281.73 287.63 -2.05 1489.73 1148.54 29.71 1489.73 1148.54 29.71
Other Income 13.99 15.09 -7.29 60.24 40.50 48.74 60.24 40.50 48.74
PBIDT 163.25 145.88 11.91 802.42 620.96 29.22 802.42 620.96 29.22
Interest 0.25 1.79 -86.03 2.01 8.28 -75.72 2.01 8.28 -75.72
PBDT 163.00 144.09 13.12 800.41 612.68 30.64 800.41 612.68 30.64
Depreciation 7.69 5.44 41.36 25.76 22.33 15.36 25.76 22.33 15.36
PBT 155.31 138.65 12.02 774.65 590.35 31.22 774.65 590.35 31.22
TAX 38.39 40.78 -5.86 194.96 154.10 26.52 194.96 154.10 26.52
Deferred Tax 0.05 0.62 -91.94 2.55 0.72 254.17 2.55 0.72 254.17
PAT 116.92 97.87 19.46 579.69 436.25 32.88 579.69 436.25 32.88
Equity 72.64 72.64 0.00 72.64 72.64 0.00 72.64 72.64 0.00
PBIDTM(%) 57.95 50.72 14.25 53.86 54.07 -0.37 53.86 54.07 -0.37
Peers
Company Name CMP
Sun Pharma. Inds. 1866.00
Dr. Reddys Labs. 1172.05
Cipla 1372.25
Lupin 2092.00
Zydus Lifesciences 1137.35
View more..